600594.SH
Guizhou Yibai Pharmaceutical Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 3.25
+0.31%Year over year
Reported trailing growth
- Revenue
- -18.2%
- EBITDA
- —
- EBIT
- -23.7%
- EPS
- -36.4%
- Free cash flow
- +414.4%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -12.0%
- EBITDA
- -25.7%
- EBIT
- +2.6%
- Net income
- -3.9%
- EPS
- -4.5%
- Free cash flow
- +114.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026